Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation

Tumor Biology

Volumn 39, Issue 3, 2017, Pages 1-15

  Seidi, Khaled ^a   Jahanban Esfahlan, Rana ^a   Zarghami, Nosratollah ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

anti angiogenesis agents; coaguligands; complete tumor ablation; tumor resistance; tumor rim cells; vascular disrupting agents; Vascular targeting agents

Indexed keywords

ANGIOGENESIS INHIBITOR; DNA VACCINE; IODINE 131; YTTRIUM 90;

ANAEROBIC BACTERIUM; ANTIANGIOGENIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG TARGETING; GENE MUTATION; HUMAN; INFARCTION; MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; SOLID MALIGNANT NEOPLASM; TUMOR ABLATION; TUMOR CELL; TUMOR RIM CELL; TUMOR VASCULARIZATION; BLOOD VESSEL; DRUG EFFECTS; DRUG RESISTANCE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; REMISSION;

ANGIOGENESIS INHIBITORS; BLOOD VESSELS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; REMISSION INDUCTION;

EID: 85016925450     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1177/1010428317691001     Document Type: Review

References (115)

1. Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 2014; 17(3): 471–494.
2. Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer 2004; 100(12): 2491–2499.
3. Jahanban-Esfahlan R, Seidi K, Zarghami N. Tumor vascular infarction: prospects and challenges. Int J Hematol 2017; 105(3): 244–256.
4. Abdollahia A, Folkman J. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat 2010; 13: 16–28.
5. Jahanban-Esfahlan R, de la Guardia M, Ahmadi D. Modulating tumor hypoxia by nanomedicine for effective cancer therapy. J Cell Physiol 2017. Doi: 10.1002/jcp.25859.
6. Fukumura D, Jain RK. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res 2007; 74(2–3): 72–84.
7. Fukumura D, Jain RK. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 2007; 101(4): 937–949.
8. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004; 10(2): 415–427.
9. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27–31.
10. Otrock ZK, Hatoum HA, Awada AH. Hypoxia-inducible factor in cancer angiogenesis: structure, regulation and clinical perspectives. Crit Rev Oncol Hematol 2009; 70: 93–102.
11. Xia Y, Choi H, Lee K. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. Eur J Med Chem 2012; 49: 24–40.
12. El-Kenawi AE, El-Remessy AB. Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales. Br J Pharmacol 2013; 170: 712–729.
13. Wahl O, Oswald M, Tretzel L. Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products. Curr Med Chem 2011; 18: 3136–3155.
14. Wang O, Dabrosinb C, Yin X. Broad targeting of angiogenesis for cancer prevention and therapy. Semin Cancer Biol 2015; 35: S224–S243.
15. Tandle A, Blazer DG, Libutti SK. Antiangiogenic gene therapy of cancer: recent developments. J Transl Med 2004; 2(22): 1–20.
16. Auerbach W, Auerbach R. Angiogenesis inhibition: a review. Pharmacol Ther 1994; 63: 265–311.
17. Augustin HG. Antiangiogenic tumour therapy: will it work? Trends Pharmacol Sci 1998; 19: 216–222.
18. Cesca M, Bizzaro F, Zucchetti M. Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents. Front Oncol 2013; 3: 1–7.
19. Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev 1990; 9: 267–282.
20. Wu XY, Ma W, Gurung K. Mechanisms of tumor resistance to small-molecule vascular disrupting agents: treatment and rationale of combination therapy. J Formos Med Assoc 2013; 112: 115e24.
21. Hinnen P, Eskens FALM. Vascular disrupting agents in clinical development. Br J Cancer 2007; 96(8): 1159–1165.
22. Gridelli C, Rossi A, Maione P. Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer. Oncologist 2009; 14(6): 612–620.
23. Ran S, Gao B, Duffy S. Infarction of solid Hodgkin’s tumors in Mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res 1998; 58: 4646–4653.
24. Guba M, Yezhelyev M, Eichhorn ME. Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. Blood 2005; 105(11): 4463–4469.
25. Samuszuk MK, Su MY, Najafi A. Selective thrombosis of tumor blood vessels in mammary adenocarcinoma implants in rats. Am J Pathol 2001; 159(1): 245–251.
26. Hu P, Yan J, Sharifi J. Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis. Cancer Res 2003; 63(16): 5046–5053.
27. Su MY, Samoszuk MK, Wang J. Assessment of protamine-induced thrombosis of tumor vessels for cancer therapy using dynamic contrast-enhanced MRI. NMR Biomed 2002; 15: 106–113.
28. Jain RK, Forbes NS. Can engineered bacteria help control cancer? Proc Natl Acad Sci U S A 2001; 98(26): 14748–14750.
29. Kubota Y. Tumor angiogenesis and anti-angiogenic therapy. Keio J Med 2012; 61(2): 47–56.
30. Jain KK. Use of bacteria as anticancer agents. Expert Opin Biol Ther Deliv 2001; 1: 291–300.
31. Gaya AM, Rustin GJ. Vascular disrupting agents: a new class of drug in cancer therapy. Clin Oncol 2005; 17(4): 277–290.
32. Huang X, Molema G, King S. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997; 275(5299): 547–550.
33. Azam F, Mehta S, Harris AL. Mechanisms of resistance to antiangiogenesis therapy. Eur J Cancer 2010; 46: 1323–1332.
34. Press OW, Eary JF, Applebaum FR. Radiolabeled antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993; 329: 1219–1224.
35. Almog N. Molecular mechanisms underlying tumor dormancy. Cancer Lett 2010; 294(2): 139–146.
36. Paez-Ribes M, Allen E, Hudock J. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15(3): 220–231.
37. Ebos JM, Lee CR, Cruz-Munoz W. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15(3): 232–239.
38. White E. The role for autophagy in cancer. J Clin Invest 125(1): 42–46.
39. Heddleston JM, Li Z, Lathia JD. Hypoxia inducible factors in cancer stem cells. Br J Cancer 2010; 102(5): 789–795.
40. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007; 129(3): 465–472.
41. Du R, Lu KV, Petritsch C. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008; 13(3): 206–220.
42. De Palma M, Nucera S. Circulating endothelial progenitors and tumor resistance to vascular-targeting therapies. Cancer Discov 2012; 2(5): 395–397.
43. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4(1): 71–78.
44. Lin EY, Pollard JW. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res 2007; 67(11): 5064–5066.
45. Welford AF, Biziato D, Coffelt SB. TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. J Clin Invest 2011; 121(5): 1969–1973.
46. Cao S, Durrania FA, Totha K. Bevacizumab enhances the therapeutic efficacy of irinotecan against human head and neck squamous cell carcinoma xenografts. Oral Oncol 2011; 47(6): 459–466.
47. Dings RPM, Laar ESV, Webber J. Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven. Cancer Lett 2008; 256(2): 270–280.
48. Volk LD, Flister MJ, Bivens CM. Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy. Neoplasia 2008; 10(6): 613–623.
49. Burrows FJ, Thorpe PE. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci U S A 1993; 90: 8996–9000.
50. Seon BK, Matsuno F, Haruta Y. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin Cancer Res 1997; 3: 1031–1044.
51. Matsuno F, Haruta Y, Kondo M. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin Cancer Res 1999; 5: 371–382.
52. Schliemann C, Palumbo A, Zuberbuhler K. Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood 2009; 113(10): 2275–2283.
53. Schwager K, Hemmerle T, Aebischer D. The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF. J Invest Dermatol 2013; 133: 751–758.
54. Gutbrodt KL, Casi G, Neri D. Antibody-based delivery of IL2 and cytotoxics eradicates tumors in immunocompetent mice. Mol Cancer Ther 2014; 13(7): 1772–1778.
55. Halin C, Gafner V, Villani ME. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Res 2003; 63(12): 3202–3210.
56. Halin C, Rondini S, Nilsson F. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 2002; 20(3): 264–269.
57. Hemmerle T, Neri D. The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer. Int J Cancer 2013; 134: 467–477.
58. Hess C, Neri D. The antibody-mediated targeted delivery of interleukin-13 to syngeneic murine tumors mediates a potent anticancer activity. Cancer Immunol Immunother 2015; 64: 635–644.
59. Pasche N, Wulhfard S, Pretto P. The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel. Clin Cancer Res 2012; 18(15): 4092–4103.
60. Pasche N, Frey K, Neri D. The targeted delivery of IL17 to the mouse tumor neo-vasculature enhances angiogenesis but does not reduce tumor growth rate. Angiogenesis 2012; 15: 165–169.
61. Pasche N, Woytschak J, Wulhfard S. Cloning and characterization of novel tumor-targeting immunocytokines based on murine IL7. J Biotechnol 2011; 154: 84–92.
62. Teramoto K, Kontani K, Fujita T. Successful tumor eradication was achieved by collaboration of augmented cytotoxic activity and anti-angiogenic eVects following therapeutic vaccines containing helper-activating analog-loaded dendritic cells and tumor antigen DNA. Cancer Immunol Immunother 2007; 56: 331–342.
63. Pedretti M, Verpelli C, Marlind J. Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma. Br J Cancer 2010; 103: 827–836.
64. Ciardiello F, Caputo R, Damiano V. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003; 9: 1546–1556.
65. Sarkar C, Chakroborty D, Chowdhury UR. Dopamine increases the efficacy of anticancer drugs in breast and colon cancer preclinical models. Clin Cancer Res 2008; 14(8): 2502–2510.
66. Song S, Yu B, Wei Y. Low-dose suramin enhanced paclitaxel activity in chemotherapy-naive and paclitaxel-pretreated human breast xenograft tumors. Clin Cancer Res 2004; 10: 6058–6065.
67. Palumbo A, Hauler F, Dziunycz P. A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels. Br J Cancer 2011; 104: 1106–1115.
68. Pedley RB, Boden JA, Boden R. Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents. Cancer Res 1996; 56: 3293–3300.
69. Pedley RB, Hill SA, Boxer GM. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin A-4 3-O-Phosphate1. Cancer Res 2001; 61: 4716–4722.
70. Siim BG, Lee AE, Shalal-Zwain S. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 2003; 51: 43–52.
71. Martinelli M, Bonezzi K, Riccardi E. Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel. Br J Cancer 2007; 97: 888–894.
72. Green C, Griffiths-Johnson D, Dunmore K. Marked potentiation of the in vivo antitumor activity of docetaxel in a human prostate cancer xenograft by the vascular targeting agent 5,6 dimethyl xanthenone acetic acid, DMXAA. Proc Amer Assoc Cancer Res 2005; 46: 2990.
73. Green C, Djeha H, Ireson C. Consistent marked potentiation of the in vivo antitumor activity of taxanes by the vascular disrupting agent, DMXAA, in lung, ovarian and prostate cancer xenografts. Proc Amer Assoc Cancer Res 2006; 47: 514.
74. Dang L, Bettegowda C, Huso D. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci U S A 2001; 98(26): 5155–15160.
75. Dang LH, Bettegowda C, Agrawal N. Targeting vascular and avascular compartments of tumors with C. novyi-NT and anti-microtubule agents. Cancer Biol Ther 2004; 3(3): 326–337.
76. Kanwar JR, Kanwar RK, Pandey S. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci. Cancer Res 2001; 61: 1948–1956.
77. Huang FY, Li YN, Wang H. A fusion protein containing murine vascular endothelial growth factor and tissue factor induces thrombogenesis and suppression of tumor growth in a colon carcinoma model. J Zhejiang Univ Sci B 2008; 9(8): 602–609.
78. Huang ZJ, Zhao Y, Luo WY. Targeting the vasculature of colorectal carcinoma with a fused protein of (RGD)(3)-tTF. Sci World J 2013; 2013: 637086.
79. Nilsson F, Kosmehl H, Zardi L. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 2001; 61: 711–716.
80. Liu C, Huang H, Donate F. Prostate-specific membrane antigen directed selective thrombotic infarction of tumors. Cancer Res 2002; 62(19): 5470–5475.
81. Bieker R, Kessler T, Schwoppe C. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience. Blood 2009; 113(20): 5019–5027.
82. Arora N, Masood R, Zheng T. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Res 1999; 59: 183–188.
83. Thorpe PE, Burrows FJ. Antibody-directed targeting of the vasculature of solid tumors. Breast Cancer Res Treat 1995; 36(2): 237–251.
84. Veenendaal LM, Jin H, Ran S. In vitro and in vivo studies of a VEGF121-rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc Natl Acad Sci U S A 2002; 99(12): 7866–7871.
85. Borsi L, Balza E, Carnemolla B. Selective targeted delivery of TNFalpha to tumor blood vessels. Blood 2003; 102(13): 4384–4392.
86. Ebbinghaus C, Ronca R, Kaspar M. Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int J Cancer 2005; 116(2): 304–313.
87. Frey K, Schliemann C, Schwager K. The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma. J Urol 2010; 184: 2540–2548.
88. Frey K, Zivanovic A, Schwager K. Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation. Integr Biol 2011; 3: 468–478.
89. Kaspar M, Trachsel E, Neri D. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. Cancer Res 2007; 67(10): 4940–4948.
90. Rouleau C, Gianolio DA, Smale R. Anti-endosialin antibody drug conjugate: potential in sarcoma and other malignancies. Mol Cancer Ther 2015; 14(9): 2081–2089.
91. Volkel T, Holig P, Merdan T. Targeting of immunoliposomes to endothelial cells using a single-chain Fv fragment directed against human endoglin (CD105). Biochim Biophys Acta 2004; 1663: 158–166.
92. Birchler M, Viti F, Zardi L. Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment. Nat Biotechnol 1999; 17: 984–988.
93. Fabbrini M, Trachsel E, Soldani P. Selective occlusion of tumor blood vessels by targeted delivery of an antibody-photosensitizer conjugate. Int J Cancer 2006; 118(7): 1805–1813.
94. Demartis S, Tarli L, Borsi L. Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin. Eur J Nucl Med 2001; 28(4): 534–539.
95. Tijink BM, Neri D, Leemans CR. Radioimmunotherapy of head and neck cancer xenografts using131 I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med 2006; 47: 1127–1135.
96. Liu S. Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjug Chem 2009; 20(12): 2199–2213.
97. Kessler T, Bieker R, Padro T. Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature. Clin Cancer Res 2005; 11(17): 6317–6324.
98. Schoenfeld JD, Dranoff G. Anti-angiogenesis immunotherapy. Hum Vaccin 2011; 7(9): 976–981.
99. Ohm JE, Gabrilovich DI, Sempowski GD. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 2003; 101: 4878–4886.
100. Griffioen AW, Damen CA, Mayo KH. Angiogenesis inhibitors overcome tumor induced endothelial cell anergy. Int J Cancer 1999; 80: 315–319.
101. Osada T, Chong G, Tansik R. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother 2008; 57: 1115–1124.
102. Dirkx AE, oude Egbrink MGA, Castermans K. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J 2006; 20: 621–630.
103. Scappaticci FA, Nolan GP. Induction of anti-tumor immunity in mice using a syngeneic endothelial cell vaccine. Anticancer Res 2003; 23: 1165–1172.
104. Hou J, Tian L, Wei Y. Cancer immunotherapy of targeting angiogenesis. Cell Mol Immunol 2004; 1: 161–166.
105. Okaji Y, Tsuno NH, Saito S. Vaccines targeting tumour angiogenesis-a novel strategy for cancer immunotherapy. Eur J Surg Oncol 2006; 32: 363–370.
106. Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and antitumour immunity. Nat Rev Cancer 2006; 6(7): 535–545.
107. Kanwar JR, Berg RW, Lehnert K. Taking lessons from dendritic cells: multiple xenogeneic ligands for leukocyte integrins have the potential to stimulate anti-tumor immunity. Gene Ther 1999; 6: 1835–1844.
108. Patyar S, Joshi R, Prasad Byrav D. Bacteria in cancer therapy: a novel experimental strategy. J Biomed Sci 2010; 17(21): 1–9.
109. Bettegowda C, Dang LH, Abrams R. Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria. Proc Natl Acad Sci U S A 2003; 100(25): 15083–15088.
110. Gardlik R, Behuliak M, Palffy R. Gene therapy for cancer: bacteria-mediated anti-angiogenesis therapy. Gene Ther 2011; 18: 425–431.
111. Westphal K, Leschner S, Jablonska J. Containment of tumor-colonizing bacteria by host neutrophils. Cancer Res 2008; 68(8): 2952–2960.
112. Zhao M, Geller J, Ma H. Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer. Proc Natl Acad Sci U S A 2007; 104(24): 10170–10174.
113. Zhao M, Yang M, Li XM. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci U S A 2005; 102(3): 755–760.
114. Agrawal N, Bettegowda C, Cheong I. Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci U S A 2004; 101(42): 15172–15177.
115. Lane DM, Eagle KF, Begent RHJ. Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab′)2 antibodies. Br J Cancer 1994; 70: 521–525.